Search results

639 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Public health guidelines Remove Public health guidelines filter
Social care guidelines Remove Social care guidelines filter

Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]

In development [GID-TA10692] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]

Proposed [GID-TA10715] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

Proposed [GID-TA10717] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

Proposed [GID-TA10718] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lifitegrast for treating dry eye disease [ID1229]

In development [GID-TA10196] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abicipar pegol for treating wet age-related macular degeneration ID1533

In development [GID-TA10511] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]

In development [GID-TA10442] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melanoma (metastatic) - talimogene laherparepvec [ID508]

In development [GID-TAG509] Expected publication date: 28 September 2016

Type

Technology appraisal guidance

Status

In development
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

In development [GID-TA10026] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

Proposed [GID-TA10426] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Psoriasis - briakinumab (suspended) [ID65]

In development [GID-TAG412] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Semaglutide for treating type 2 diabetes (ID1450)

Proposed [GID-TA10438] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

Proposed [GID-TA10297] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pegvaliase for treating phenylketonuria [ID1110]

Proposed [GID-TA10345] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Osteoarthritis - naproxcinod [ID417]

In development [GID-TAG426] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]

In development [GID-TAG418] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

In development [GID-TAG456] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (acute lymphoblastic) - dasatinib [ID386]

In development [GID-TAG399] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]

In development [GID-TAG398] Expected publication date: 01 January 2011

Type

Technology appraisal guidance

Status

In development
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

In development [GID-TAG414] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Diabetic foot ulcers - new treatments [ID381]

In development [GID-TAG371] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous leg ulcers - new treatments [ID394]

In development [GID-TAG370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism (VTE) - ximelagatran [ID396]

In development [GID-TAG378] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]

In development [GID-TA10209] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]

In development [GID-TA10690] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083]

In development [GID-TA10260] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588

In development [GID-TA10507] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]

In development [GID-TA10614] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]

In development [GID-TA10618] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 23 June 2021

Type

Technology appraisal guidance

Status

In development
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]

Proposed [GID-TA10740] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

In development [GID-TA10512] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Selumetinib for treating inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]

Proposed [GID-TA10535] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]

In development [GID-TA10615] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

In development [GID-TA10375] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

In development [GID-TA10484] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Baloxavir marboxil for treating influenza [ID1537]

In development [GID-TA10559] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

In development [GID-TA10544] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Apalutamide for treating prostate cancer [ID1534]

In development [GID-TA10423] Expected publication date: 26 May 2021

Type

Technology appraisal guidance

Status

In development
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Short bowel syndrome - teduglutide [ID885]

In development [GID-TA10048] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]

In development [GID-TA10466] Expected publication date: 28 April 2021

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]

In development [GID-TA10564] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development